Fiche publication
Date publication
septembre 2017
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MALOUF Gabriel
Tous les auteurs :
Campedel L, Kossaï M, Blanc-Durand P, Rouprêt M, Seisen T, Compérat E, Spano JP, Malouf G
Lien Pubmed
Résumé
Neuroendocrine prostate cancer is a rare malignancy with a an adverse prognostic. Histologically, It can be pure (small cells or large cells neuroendocrine carcinoma) or mixed with a adenocarcinoma component. Rarely diagnosed de novo, neuroendocrine prostate cancer is generally associated with advanced stage disease resistant to castration. As such, this histological subtype could represent an aggressive evolution of prostatic adenocarcinoma, through the epithelio-neuroendocrine transdifferentiation mechanism (phenomenon of lineage plasticity). Nonetheless, neuroendocrine prostate cancer is a heterogeneous malignancy with multiple histopathological variants showing distinct clinical features. The broad variety of molecular analyses could help to understand the ontogeny of this histological subtype and its signaling pathways. This may also allow identifying diagnostic and prognostic biomarkers as well as potential molecular targets. However, treatment options are currently limited and consist only in platinium-based chemotherapy for advanced stage disease.
Mots clés
Adenocarcinoma, pathology, Antineoplastic Agents, therapeutic use, Carcinoma, Neuroendocrine, diagnostic imaging, Humans, Immunohistochemistry, Male, Phenotype, Platinum Compounds, therapeutic use, Prostatic Neoplasms, diagnostic imaging, Rare Diseases, diagnostic imaging
Référence
Bull Cancer. 2017 Sep;104(9):789-799
